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Membrane type 1–matrix metalloproteinase is involved in migration of human
monocytes and is regulated through their interaction
with fibronectin or endothelium
Salomo´n Matı´as-Roma´n, Beatriz G. Ga´lvez, Laura Genı´s, Marı´a Ya´n˜ez-Mo´, Gonzalo de la Rosa, Paloma Sa´nchez-Mateos,
Francisco Sa´nchez-Madrid, and Alicia G. Arroyo
Membrane type 1–matrix metalloprotein-
ase (MT1-MMP) is involved in endothelial
and tumor-cell migration, but its putative
role in leukocyte migration has not been
characterized yet. Here, we demonstrate
that anti–MT1-MMP monoclonal antibody
(mAb) impaired monocyte chemotactic
protein-1 (MCP-1)–stimulated monocyte
migration on fibronectin (FN), vascular
cell adhesion molecule-1 (VCAM-1), and
intercellular adhesion molecule-1 (ICAM-
1). In addition, monocyte transmigration
through tumor necrosis factor- (TNF-)–
activated endothelium is also inhibited by
anti–MT1-MMP mAb. Therefore, regula-
tion of MT1-MMP in human peripheral
blood monocytes was investigated. First,
MT1-MMP clustering was observed at mo-
tility-associated membrane protrusions of
MCP-1–stimulated monocytes migrating
on FN, VCAM-1, or ICAM-1 and at the
leading edge, together with profilin, of
monocytes transmigrating through acti-
vated endothelial cells. In addition, up-
regulation of MT1-MMP expression was
induced in human monocytes upon at-
tachment to FN in a manner dependent on
41 and 51 integrins. Binding of
monocytes to TNF-–activated human
endothelial cells as well as to VCAM-1 or
ICAM-1 also resulted in an increase of
MT1-MMP expression. These findings cor-
related with an enhancement of MT1-MMP
fibrinolytic activity in monocytes bound
to FN, VCAM-1, or ICAM-1. Our data show
that MT1-MMP is required during human
monocyte migration and endothelial trans-
migration and that MT1-MMP localization,
expression, and activity are regulated in
monocytes upon contact with FN or endo-
thelial ligands, pointing to a key role of
MT1-MMP in monocyte recruitment dur-
ing inflammation. (Blood. 2005;105:
3956-3964)
© 2005 by The American Society of Hematology
Introduction
Monocyte recruitment to tissues is a key event during inflammatory
responses. Many proteins participate in the cellular interactions
established during monocyte extravasation. Thus, selectins and
integrins play important roles during tethering, rolling, and firm
adhesion to endothelium, and chemokines and proteins at the
endothelial junctions such as platelet endothelial cell adhesion
molecule-1 (PECAM-1), junctional adhesion molecule-1 (JAM-1),
and vascular endothelial (VE)–cadherin are also critical for that
process.1 Recently, an additional step in monocyte extravasation
called locomotion on the endothelium has been described.2 After
endothelial transmigration, monocytes must traverse tissue barriers
composed of distinct structural proteins; the subendothelial base-
ment membrane is a dense and continuous meshwork of proteins
that include laminin, type IV collagen, entactin, and proteoglycans,
and the interstitial matrix is rich in type I and III fibrillar collagens
and fibronectin (FN). In addition, a provisional matrix of fibrin is
often deposed in case of vascular injury. The degradation of these
extracellular matrix (ECM) components is an essential requirement
for monocyte transmigration and requires the proteolytic action of
specific enzymes.
The matrix metalloproteinase (MMP) family consists of Zn-
dependent endopeptidases and is in charge of degrading ECM
components during physiologic and pathologic processes such as
wound healing and tumor invasion.3 MMPs are generally grouped
according to their structure. MMPs contain a procatalytic and a
catalytic domain, and each subfamily has additional function-
specific domains such as the hemopexin domain or the membrane-
anchorage domain in the case of membrane-type MMPs. MMPs are
regulated at the levels of transcription, posttranslational activation
because they are secreted as zymogens, and inhibition by endoge-
nous tissue inhibitors. The ratio of activation to inhibition deter-
mines the net balance of cellular proteolytic activity.4 A fine-tuned
spatiotemporal regulation of the proteolytic activity is required for
focused degradation of the ECM during extravasation, and mem-
brane-anchored MMPs, and membrane type 1–MMP (MT1-MMP)
in particular, are especially suited for pericellular proteolysis.5
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MT1-MMP displays a wide range of proteolytic activities. It
degrades ECM components such as gelatin, FN, laminin, vitronec-
tin, fibrillar collagens, and fibrin; activates proMMP-2 (through the
formation of a trimolecular complex together with tissue inhibitor
of metalloproteinase-2 [TIMP-2]) and proMMP-13; cleaves CD44,
tissue transglutaminase, and integrin v; and processes latent
tumor growth factor- (TGF-).6 MT1-MMP plays important roles
in tumor invasion and endothelial cell migration during angiogen-
esis,7,8 and it has been hypothesized that leukocytes might use
similar proteolytic mechanisms to migrate to and invade tissues.
Nevertheless, the role and function in leukocyte physiology of
MMPs in general and of MT1-MMP in particular remain
largely unknown.
The potential role of MT1-MMP in monocyte recruitment is
highlighted by the occurrence of this protease in inflammatory
infiltrates from several pathologies. Thus, MT1-MMP has been
found in macrophages in human atherosclerotic plaques9 and in
macrophage-like cells in normal and pathologic synovial tissue in
rheumatoid arthritis.10 MT1-MMP and its target MMP-2 have also
been shown to be important in lymphocyte recruitment during
murine experimental allergic encephalomyelitis.11 These findings
suggest that MT1-MMP might be involved in leukocyte transmigra-
tion during the inflammatory response. Although peripheral blood
monocytes do not constitutively produce proMMP-2, the induction
of its activator MT1-MMP in human monocytes stimulated with
lipopolysaccharide (LPS) has been reported recently.12 However,
its putative function in these cells has not been elucidated yet.
In this report, we characterize the role of MT1-MMP during
monocyte migration and endothelial transmigration and its regulation
through monocyte interaction with either FN or endothelial ligands.
Materials and methods
Antibodies and reagents
Anti–MT1-MMP LEM-2/15, anti–major histocompatibility complex-I (anti–
MHC-I) W6/32, and anti-CD45 D3/9 monoclonal antibodies (mAbs) have
been used previously.7,13,14 The Ab 2H11 against profilin was a gift from Dr
B. M. Jockusch (Zoological Institute, Braunschweig, Germany). Anti–-
actin was from Sigma Chemical (St Louis, MO). Human tumor necrosis
factor- (TNF-) and monocyte chemotactic protein-1 (MCP-1) were from
R&D Systems (Minneapolis, MN). Human -globulin, LPS, bovine serum
albumin (BSA), gelatin, and FN were purchased from Sigma. Plasminogen-
depleted plasma-derived fibrinogen was from Calbiochem-Novabiochem
(Darmstadt, Germany). Recombinant forms of intercellular adhesion mole-
cule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) fused
to Fc have been described previously.13 Proteolytic fragments of FN, H89
and FN80, were a gift from Dr A. Garcı´a-Pardo (Centro de Investigaciones
Biolo´gicas, Madrid, Spain) and have been characterized previously.15,16 All
substrates used were tested for the presence of endotoxin with the E-Toxate
kit (Sigma) and proved to be endotoxin free.
Cells and cell cultures
Peripheral blood monocytes were isolated from human blood by sequential
centrifugation in density gradients of Ficoll-Hypaque and Percoll (Amer-
sham Pharmacia Biotech, Buckinghamshire, United Kingdom; and Sigma)
as described.17 Samples of monocytes in which more than 30% constitu-
tively expressed MT1-MMP were excluded from the analysis. For func-
tional assays, cells were cultured in RPMI 1640 medium (Flow Lab, Irvine,
United Kingdom) supplemented with 0.5% BSA. Human umbilical vein
endothelial cells (HUVECs) were obtained and cultured as described
previously, and cells at passage 3 or below were used in all assays.7
Approval was obtained from the Hospital Universitario de la Princesa
institutional review board for these studies.
Cell migration assay
Migration assays were performed in 3 m–pore Transwell chambers
(Costar, Cambridge, MA). For this assay, total peripheral blood mono-
nuclear cells (PBMCs) obtained from the Ficoll-Hypaque gradient were
used. A total of 106 PBMCs were resuspended in 150 L RPMI 1640
medium, 0.5% BSA. Cells were preincubated with 20 g/mL human
-globulin for 20 minutes and then with 15 g/mL anti–MT1-MMP
LEM-2/15 or anti–MHC-I W6/32 as isotype-matched control mAb for
another 20 minutes. Control samples were incubated in phosphate-buffered
saline (PBS). Next, cells were added to the upper chamber of Transwell
filters that had been previously coated with 20 g/mL FN or 10 g/mL
VCAM-1 or ICAM-1. A total of 10 nM MCP-1 was added to the lower
chamber. Migrated monocytes were identified and quantitated after 2 hours
by flow cytometric or microscopic analysis of total (suspended and
adhered) cells in the lower chamber. Migrated monocytes were represented
as the percentage of the total cellular input. Assays were run in triplicate.
Endothelial transmigration assays
Transmigration assays were performed in 3 m–pore Transwell chambers
(Costar). A total of 105 HUVECs were plated on gelatin-coated filters for 24
hours and either left unstimulated or stimulated for 2 hours with 20 ng/mL
TNF-. A total of 5  105 PBMCs were resuspended in 150 L RPMI 1640
medium, 0.5% BSA, preincubated with 20 g/mL human -globulin for 20
minutes, and then incubated with 15 g/mL anti–MT1-MMP LEM-2/15 or
anti–MHC-I W6/32 as isotype-matched control mAb for another 20
minutes. Control PBMCs were incubated in PBS. PBMCs were then added
to the upper chamber of Transwells containing the resting or activated
endothelial cell monolayer. A total of 10 nM MCP-1 was added to the lower
chamber. Transmigrated monocytes were identified and quantitated after 2
hours by flow cytometric or microscopic analysis of total (suspended and
adhered) cells in the lower chamber. Migrated monocytes were represented
as the percentage of the total cellular input. Assays were run in triplicate.
Immunofluorescence microscopy
Monocytes were attached at 8  105 cells per milliliter to 0.5% BSA-, 20
g/mL FN-, or 10 g/mL VCAM-1– or ICAM-1–coated coverslips for 2 or
16 hours at 37°C and stimulated with 10 nM MCP-1 for the last 2 hours.
Cells were fixed with 4% paraformaldehyde, blocked with tris(hydroxy-
methyl)aminomethane (Tris)–buffered saline plus 0.5% blocking reagent
(TNB, Boehringer Mannheim, Mannheim, Germany), and then incubated
sequentially for 30 minutes at 37°C with 20 g/mL human -globulin,
anti–MT1-MMP LEM-2/15 mAb, and fluorescein isothiocyanate (FITC)–
goat antimouse mAb and Texas Red–phalloidin (Molecular Probes, Eugene,
OR). Samples were examined in a Leica DMR photomicroscope equipped
with a 100/1.4 oil immersion objective, and images were photographed
with a Leica CCD camera. Images were acquired with Leica QFish software
and processed with Adobe Photoshop 6.0 software (Adobe, San Jose, CA).
For quantitation of monocytes with MT1-MMP clusters, at least 100 cells
per condition were counted by 2 independent observers.
Confocal microscopy
Monocytes were added in the presence of 10 nM MCP-1 to endothelial cells
previously activated for 12 hours with TNF-. After 2 hours, cells were
fixed with 4% paraformaldehyde and double stained with anti-CD45 D3/9
or antiprofilin 2H11 and biotinylated anti–MT1-MMP LEM-2/15 primary
mAbs. Secondary reagents were rhodamine X–goat antimouse mAb and
streptavidin–Alexa-488. Samples were mounted and analyzed with a Leica
confocal microscope.
Flow cytometry analysis
Monocytes were incubated on distinct substrates for specified times and
then detached with enzyme-free Hanks-based cell dissociation buffer
(Invitrogen Life Technologies, Karlsruhe, Germany). Cells were next
labeled by sequential incubation for 30 minutes at 4°C with 20 g/mL
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human -globulin, anti–MT1-MMP LEM-2/15 mAb, and FITC-goat anti-
mouse mAb. Monocytes attached to VCAM-1 or ICAM-1 recombinant
proteins were labeled by incubation with human -globulin, primary
biotinylated anti–MT1-MMP LEM-2/15 mAb, and FITC-avidin to avoid
any background staining from the Fc. Finally, samples were analyzed in a
FACSCalibur (Becton Dickinson Labware, Lincoln Park, NJ).
Western blot assays
Monocytes were incubated on distinct substrates for specified times. Next,
they were washed twice with PBS and directly lysed in Laemmli buffer on
ice. Lysates were resolved on 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) under reducing conditions, and the
proteins were transferred to a nitrocellulose membrane from Pierce
Biotechnology (Rockford, IL). The membrane was blocked with 5% nonfat
milk or BSA in TBS-T (Tris-buffered saline plus 0.05% Tween 20) and
incubated with anti–MT1-MMP LEM-2/15 mAb culture supernatant and
then with a horseradish peroxidase (HRP)–conjugated anti–mouse immuno-
globulin G (IgG) antibody. Anti–-actin at 1:5000 dilution was used as a
loading control. Protein bands were visualized by enhanced chemiluminis-
cence (ECL; Amersham Pharmacia Biotech). Densitometric analysis was
performed on scanned images with Image Gauge Software from Fuji Photo
Film (Du¨sseldorf, Germany).
Zymography assays
Monocytes were incubated on distinct substrates for specified times. They
were then washed twice with PBS and directly lysed in Laemmli buffer on
ice. Samples were resolved under nonreducing conditions on 10% SDS-
PAGE gels embedded with 1 mg/mL fibrinogen. After electrophoresis, gels
were rinsed in 2.5% Triton X-100 for 3  60 minutes and in distilled water
for 2  20 minutes at room temperature (RT) and finally incubated in 50
mM Tris-HCl pH 7.5, 10 mM CaCl2, and 200 mM NaCl for 16 hours at
37°C. Gels were stained with Coomassie blue, and areas of fibrinolytic
activity were visualized as transparent bands.
Statistical analysis
Test and control samples in the functional assays were compared for
statistical significance by using the Student t test.
Results
MT1-MMP is required for migration of human monocytes on FN,
VCAM-1, or ICAM-1, and for their transmigration
through activated endothelium
It has recently been shown that MT1-MMP is expressed in human
monocytes stimulated with LPS.12 We therefore decided to explore
MT1-MMP function in primary human monocytes isolated from
peripheral blood. It has previously been suggested that LPS-
induced MT1-MMP in monocytes might play a role in activating
tumor or stroma-derived proMMP-2.12 However, because MT1-
MMP per se displays an important proteolytic activity and has been
implicated in migration of other cell types, we first investigated
whether MT1-MMP might be participating directly in the migra-
tory properties of monocytes.
To this purpose, the effect of the inhibitory anti–MT1-MMP
LEM-2/15 mAb was assessed in the migration of human mono-
cytes on distinct substrates they can find in their path to the
inflammatory focus. As shown in Figure 1A, this mAb significantly
inhibited migration on FN of freshly isolated monocytes toward the
chemokine MCP-1 by about 60%, in contrast with the anti–MHC-I
W6/32 mAb used as an isotype-matched control. Because mono-
cytes need to migrate on the endothelial cells before transmigra-
tion,2 the role of MT1-MMP on monocyte migration on two of the
most important endothelial ligands involved in leukocyte attach-
ment VCAM-1 and ICAM-1, ligands for integrins 4 and 2,
respectively, was analyzed by using recombinant forms fused to
Fc.13 The inhibitory anti–MT1-MMP LEM-2/15 mAb significantly
decreased monocyte migration on immobilized VCAM-1 or
ICAM-1 toward MCP-1 by 40% and 30%, respectively, whereas
the control W6/32 mAb had no effect (Figure 1B-C). Anti–MT1-
MMP mAb did not, however, impair monocyte migration on bare
filters (Figure 1D).
Monocyte transendothelial migration is a key step during the
inflammatory response. The putative role of MT1-MMP in this
process was next investigated. As shown in Figure 2A, preincuba-
tion of freshly isolated monocytes with the anti–MT1-MMP
Figure 1. MT1-MMP activity is required for MCP-1–stimulated migration of
monocytes on FN, VCAM-1, or ICAM-1. Monocyte migration was analyzed in
Transwell assays on 3 m–pore filters coated with 20 g/mL FN, 10 g/mL VCAM-1
or ICAM-1, or none (A, B, C, and D, respectively). MCP-1 (100 ng/mL) or vehicle was
added to the lower chamber. Monocytes were pretreated with PBS or 15 g/mL
anti–MT1-MMP LEM-2/15 mAb or the isotype-matched control anti–MHC-I W6/32
mAb. Migrated cells were quantitated after 2 hours as described in “Materials and
methods” and are represented as a percentage of cellular input. The arithmetic
means and SD of n independent experiments run in triplicate are shown (n  4 for
FN, n  3 for VCAM-1, n  4 for ICAM-1, and n  3 for none). ***P  .01.
Figure 2. MT1-MMP plays a role in MCP-1–induced transmigration of mono-
cytes through activated endothelial cells. Monocyte transmigration was analyzed
in Transwell assays on 3 m–pore filters coated either with endothelial monolayers
previously activated with 20 ng/mL TNF- for 2 hours (A) or with resting endothelial
monolayers (B). MCP-1 (100 ng/mL) or vehicle was added to the lower chamber.
Monocytes were pretreated with PBS or 15 g/mL anti–MT1-MMP LEM-2/15 mAb or
the isotype-matched control anti–MHC-I W6/32 mAb. Transmigrated cells were
quantitated after 2 hours as described in “Materials and methods” and are repre-
sented as the percentage of cellular input. The arithmetic means and SD of 3
independent experiments run in triplicate are shown. ***P  .01.
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LEM-2/15 mAb significantly inhibited their transmigration through
TNF-–activated endothelial monolayers toward MCP-1 by 40%,
in contrast to no effect of the isotype-matched control anti–MHC-I
W6/32 mAb. However, the anti–MT1-MMP mAb barely affected
monocyte transmigration through resting endothelial cells
(Figure 2B).
MT1-MMP is localized at motility-associated membrane
protrusions in MCP-1–stimulated monocytes
migrating on FN, VCAM-1, or ICAM-1
MT1-MMP subcellular localization is important for its activity.7,18
Because MT1-MMP was playing a role in monocyte migration on
FN, VCAM-1, and ICAM-1, its subcellular localization on mono-
cytes migrating on these substrates was next analyzed by indirect
immunofluorescence. For this, monocytes were incubated on FN,
VCAM-1, or ICAM-1 for 2 hours in the presence of MCP-1.
Monocytes spread and displayed distinct membrane protrusions
such as lamellipodia (extensions) and filopodia (elongations) when
migrating on the different substrates, as revealed by F-actin
staining and interference contrast (Figure 3A). Remarkably, MT1-
MMP was clustered along lamellipodia of monocytes migrating on
FN, VCAM-1, or ICAM-1 for 2 hours (Figure 3A). A diffuse
staining of MT1-MMP was, however, observed in monocytes
attached to BSA (data not shown). The percentage of monocytes
displaying MT1-MMP clusters was 40% on FN, 49% on VCAM-1,
and 35% on ICAM-1 compared with 8% on BSA. Similarly,
MT1-MMP was localized along filopodia in MCP-1–stimulated
monocytes attached to FN, VCAM-1, or ICAM-1 for 16 hours
(Figure 3B); in this case, the percentage of monocytes with
MT1-MMP clusters was 26% on FN, 36% on VCAM-1, and 27%
on ICAM-1 compared with 15% on BSA.
MT1-MMP is present at the leading edge of monocytes
migrating on activated human endothelial cells
Because a role of MT1-MMP was observed in monocyte transmi-
gration through activated endothelium, its subcellular localization
was next analyzed in this context. Freshly isolated human mono-
cytes were bound for 2 hours to monolayers of TNF-–activated
endothelial cells in the presence of MCP-1 to induce their
polarization and migration (Figure 4A). Anti-CD45 staining was
included to identify monocyte membranes, because MT1-MMP is
also present in endothelial cells (Figure 4). Confocal sections show
monocytes at different levels: on top of, spread over, and transmi-
grated underneath the endothelial monolayer. Interestingly, MT1-
MMP present at the monocyte cell membrane (colocalizing with
CD45) was mainly clustered at the extended lamellipodia of
Figure 3. MT1-MMP relocalizes to motility-associated
membrane protrusions in monocytes migrating on
FN, VCAM-1, or ICAM-1. MT1-MMP (green) and F-actin
(red) were immunostained in monocytes attached to
plates coated with 20 g/mL FN or 10 g/mL VCAM-1 or
ICAM-1 for 2 hours (A) or 16 hours (B) and stimulated
with 100 ng/mL MCP-1 for the last 2 hours. Differential
interference contrast (DIC) images are shown in the
insets as controls of cell morphology. Arrowheads indi-
cate cellular membrane protrusions, lamellipodia and
filopodia, where MT1-MMP is clustered.
Figure 4. MT1-MMP is enriched at the leading edge of monocytes migrating on
activated endothelial cells. (A) MT1-MMP (green) and CD45 (red) were stained in
fresh monocytes adhered for 2 hours in the presence of 100 ng/mL MCP-1 to
endothelial cells previously stimulated with 20 ng/mL TNF- for 12 hours. Selected
confocal sections and the merged overlay of all sections are presented. Arrowheads
indicate areas where MT1-MMP and CD45 colocalize at monocyte membrane ruffles.
(B) MT1-MMP (green) and profilin (red) were stained in fresh monocytes adhered for
2 hours in the presence of 100 ng/mL MCP-1 to endothelial cells previously
stimulated with 20 ng/mL TNF- for 12 hours. Selected confocal sections and the
merged overlay of all sections are presented. Arrowheads indicate areas where
MT1-MMP and profilin colocalize at monocyte leading edge.
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polarized monocytes transmigrating through activated endothe-
lium; in some cases, MT1-MMP could also be observed at the
opposite site (Figure 4A).
To explore further the subcellular compartmentation of MT1-
MMP in monocytes transmigrating through activated endothelium,
double staining with profilin, a marker of cellular leading edge,19
was performed and analyzed by confocal microscopy. As shown in
Figure 4B, MT1-MMP nicely colocalized with profilin at the
leading edge of MCP-1–stimulated monocytes migrating on acti-
vated endothelial cells.
MT1-MMP expression is up-regulated in human peripheral
blood monocytes upon attachment to FN in a manner
dependent on 41 and 51 integrins
As herein shown, MT1-MMP is required for monocyte migration
on FN, and the protease is relocalized in monocytes migrating on
this matrix. Therefore, additional mechanisms of regulation were
investigated. Because the ECM can modulate MMP expression in
different cell types,18,20 we next tested whether interaction with FN
might regulate MT1-MMP expression in human monocytes. No
changes in MT1-MMP surface expression were observed in
monocytes attached to FN for 2 hours (data not shown). However,
MT1-MMP expression was up-regulated on the cell surface of
human monocytes attached to FN for 16 hours compared with
freshly isolated cells or cells attached to BSA, as analyzed by flow
cytometry with the anti–MT1-MMP mAb LEM-2/15 (Figure 5A).
LPS was included as a positive control. Constitutive MT1-MMP
expression was often observed at the cell surface of freshly isolated
monocytes, as was a slight increase upon attachment to BSA.
Nonetheless, the increment upon binding to FN was greater and
significant (Figure 5B).
FN can be recognized by different cell adhesion receptors,
including the integrin superfamily members 41 and 51
integrins.21 To investigate whether these receptors might be in-
volved in FN-stimulated MT1-MMP expression, human mono-
cytes were adhered to FN fragments H89 and FN80. These
fragments have previously been characterized as distinct ligands of
integrins 41 and 51, respectively,15,16 and we confirmed this
in monocyte adhesion assays (data not shown). Attachment of
human monocytes to either fragment H89 or FN80 induced
significant increases in cell-surface expression of MT1-MMP,
similar to those obtained with full-length FN from human plasma
(Figure 5A-B). Therefore, the effect of different doses of these
substrates was analyzed. As shown in Figure 5C, MT1-MMP
surface up-regulation was similar in monocytes on either FN, H89,
or FN80 at 10 g/mL; however, H89 seemed to be slightly more
Figure 5. MT1-MMP expression is up-regulated in human monocytes attached to FN in a manner dependent on 41 and 51 integrins. (A) MT1-MMP cell-surface
expression was analyzed by flow cytometry in freshly isolated monocytes (thin solid line) and in monocytes attached to plates coated with 0.5% BSA, 20 g/mL FN, or 10 g/mL
FN fragments H89 and FN80 for 16 hours (thick solid line). LPS stimulation (10 ng/mL) for 16 hours was included as a positive control. X63 was used as a negative control of
staining (dotted line). One independent experiment of 6 is represented. (B) The arithmetic means and SD are shown of the percentage of MT1-MMP–positive monocytes
(subtracting X63 negative control values) under different conditions. n  6. *P  .05 (versus fresh) and **P  .04 (versus BSA). (C) MT1-MMP cell-surface expression was
analyzed as described in panel A in monocytes adhered for 16 hours to different doses of BSA, FN, or FN fragments H89 and FN80 as indicated. The arithmetic means of the
percentage of MT1-MMP–positive monocytes (subtracting X63 negative control values) are represented for each condition. n  3. (D, top) MT1-MMP protein content was
estimated by Western blot analysis of total cellular extracts from fresh monocytes or monocytes attached to plates coated as described for panel A. Anti–MT1-MMP LEM-2/15
mAb recognizes immature and mature forms of MT1-MMP of 63 and 60 kDa, respectively. (D, bottom) The arithmetic means and SD of the fold induction of the ratio of
MT1-MMP to -actin levels estimated by densitometry are represented (an arbitrary value of 1 was assigned to the MT1-MMP/-actin ratio in freshly isolated monocytes).
n  4. ***P  .01.
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efficient at lower doses, suggesting that 4 integrin binding site is
not fully active in FN, as reported previously.16 In addition,
incubation of monocytes for 16 hours with soluble FN at 20 g/mL
up-regulated MT1-MMP surface expression up to 40%, close to
values obtained with immobilized FN. These data suggest that
integrin receptor occupancy by the ligand rather than its aggrega-
tion plays the major role in MT1-MMP up-regulation.
We next analyzed the total amount of MT1-MMP protein in
monocyte total cell lysates by Western blot with the anti–MT1-
MMP LEM-2/15 mAb. As shown in Figure 5D, both MT1-MMP
immature and mature forms (63 and 60 kDa, respectively) are
detected in lysates of monocytes under the different conditions. The
total amount of MT1-MMP is significantly increased in monocytes
attached to FN or its fragments H89 or FN80 during 16 hours
compared with fresh monocytes or monocytes bound to BSA
(Figure 5D). LPS was included as a positive control. These data and
the kinetics of the up-regulation at the cell surface together suggest
that MT1-MMP protein synthesis is increased in monocytes
adhered to FN.
MT1-MMP expression is also increased in human monocytes
upon binding to activated human endothelial cells
or to VCAM-1 or ICAM-1
A role of MT1-MMP was observed in monocyte transmigration
through activated endothelium (Figure 2A), and the protease was
clustered at the leading edge of monocytes transmigrating through
activated endothelial cells (Figure 4). Therefore, modulation of
MT1-MMP expression under these conditions was next tested.
Attachment of freshly isolated monocytes to activated endothelial
cells for 2 hours did not have any effect on MT1-MMP surface
expression (data not shown). However, monocyte binding to
TNF-–activated human endothelial cells for 16 hours resulted in a
significant increase in MT1-MMP cell-surface expression, as
demonstrated by flow cytometry (Figure 6A-B). We then analyzed
the contribution of VCAM-1 and ICAM-1. Monocyte binding to
immobilized VCAM-1 or ICAM-1 for 16 hours significantly
up-regulated MT1-MMP cell-surface expression compared with
freshly isolated monocytes as assessed by flow cytometry (Figure
6A-B). Similarly to FN or its fragments, efficient MT1-MMP
surface up-regulation occurred in monocytes on immobilized
VCAM-1 or ICAM-1 at 10 g/mL (Figure 6C).
Flow cytometry data were also confirmed by Western blot
analysis. As shown in Figure 6D, MT1-MMP protein content was
significantly increased in human monocytes attached to either
VCAM-1 or ICAM-1 compared with freshly isolated or BSA-
adhered monocytes.
Enhancement of MT1-MMP fibrinolytic activity in monocytes
bound to FN, VCAM-1, or ICAM-1
Because MT1-MMP proteolytic activity depends on its subcellular
localization and expression7,19,21 and MT1-MMP was clustered and
Figure 6. Up-regulation of MT1-MMP expression in monocytes bound to activated endothelium or VCAM-1 or ICAM-1 ligands. (A) MT1-MMP cell-surface expression
was analyzed by flow cytometry of fresh isolated monocytes (thin solid line) and of monocytes attached for 16 hours to endothelium stimulated with 20 ng/mL TNF- for 12
hours. MT1-MMP cell-surface expression was also analyzed in monocytes attached to plates coated with 10 g/mL recombinant forms of VCAM-1 or ICAM-1 for 16 hours. X63
or labeled avidin was used as negative controls of staining of monocytes on endothelium or on VCAM-1 or ICAM-1, respectively (dotted line). One independent experiment of 3
is represented. (B) The arithmetic means and SD of the percentage of MT1-MMP–positive monocytes (subtracting X63 or labeled-avidin negative control values) under
different conditions are shown. n  3. *P  .05 (versus fresh) and **P  .04 and ***P  .01 (versus BSA). (C) MT1-MMP cell-surface expression was analyzed as described in
panel A in monocytes adhered for 16 hours to different doses of BSA, VCAM-1, or ICAM-1. The arithmetic means of the percentage of MT1-MMP–positive monocytes
(subtracting labeled-avidin negative control values) are represented for each condition. n  3. (D) MT1-MMP protein content was estimated by Western blot analysis of total
cellular extracts from fresh monocytes or monocytes attached to plates coated as described for panel A. LPS stimulation for 16 hours was included as a positive control.
Anti–MT1-MMP LEM-2/15 mAb recognizes immature and mature forms of MT1-MMP of 63 and 60 kDa, respectively. The arithmetic means and SD of the fold induction of the
ratio of MT1-MMP to -actin levels estimated by densitometry are represented (an arbitrary value of 1 was assigned to the MT1-MMP/-actin ratio in freshly isolated
monocytes). n  4. ***P  .01.
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up-regulated upon attachment of monocytes to FN, VCAM-1, or
ICAM-1, we next analyzed its activity under these conditions by
fibrinogen zymography. As shown in Figure 7, cell lysates from
control monocytes attached to BSA for 16 hours displayed a
fibrinolytic band of about 60 kDa, corresponding to the mature
form of MT1-MMP. Remarkably, MT1-MMP fibrinolytic activity
was significantly increased upon attachment of monocytes for 16
hours to FN or its fragments H89 and FN80, as well as to VCAM-1
or ICAM-1, compared with monocytes on BSA (Figure 7). No
increase in MT1-MMP fibrinolytic activity was detected upon
shorter times of monocyte attachment to the substrates (data not
shown). The enhancement of MT1-MMP activity was likely related
to the increase of its expression induced by the different substrates
(Figures 5D and 6D).
Discussion
Monocyte extravasation into tissues is a key process during the
inflammatory response. In this report, we provide the first demon-
stration that MT1-MMP activity is required for proper migration
and endothelial transmigration of primary human monocytes. We
have also characterized the regulation of MT1-MMP localization,
expression, and activity in primary human monocytes through their
interaction with FN or endothelial ligands.
The suggested role of MMPs in leukocyte recruitment has up to
now been elusive. Recently, the induction of MT1-MMP in human
monocytes stimulated with LPS suggested a role for this protease in
monocyte physiology.12 However, because monocytes do not
secrete MMP-2, the authors proposed that MT1-MMP might be
involved in activation of stroma- or tumor-derived proMMP-2.
Because MT1-MMP displays a relevant proteolytic activity itself
and it has been implicated in the migration of several cell types,
including endothelial and tumor cells,7,8 its putative role in
monocyte migration was first investigated. Monocytes must inter-
act with both endothelial cells and a variety of ECM components
on their path to the inflammatory foci. In this regard, we first show
that MT1-MMP is required for migration of human monocytes on
FN and on the endothelial ligands VCAM-1 or ICAM-1. The
functional assays were performed in freshly isolated monocytes,
highlighting the importance of MT1-MMP in a physiologic situa-
tion. MT1-MMP can modulate cell migration by proteolysis of the
substrate to unmask cryptic adhesion sites and by regulation of
adhesion/deadhesion properties of receptors such as CD44, tissue
transglutaminase, and integrins.6 The actual mechanisms through
which MT1-MMP modulates monocyte migration are as yet
undetermined. Substrate proteolysis to expose new adhesion sites
might play a role in migration on ECM but is less likely on
endothelial ligands despite the reported ability of proteases of the
ADAM (a disintegrin and metalloproteinase) family to shed
VCAM-1 from the cell membrane.22 Moreover, MT1-MMP could
be processing tissue transglutaminase receptor, a coreceptor for FN
in monocytes, thus regulating their adhesion and migration.23,24
Alternatively or additionally, MT1-MMP could be modulating 1
and/or 2 integrin receptor function during monocyte migration. In
this regard, v integrin function can be modulated by MT1-MMP,
and the biochemical and/or functional association of MT1-MMP
with integrins 1 and v have been reported in other cell types.18,25
Interestingly, 2 integrin–mediated monocyte locomotion has been
identified recently as a critical additional step during extravasa-
tion.2 It is tempting to speculate that MT1-MMP might be relevant
for proper regulation of this step.
The final step of extravasation involves monocyte passage
through the endothelial junctions, where molecules such as PE-
CAM-1, JAM-1, and VE-cadherin are important.1 A role for MMPs
in this process has been suggested by the up-regulation of MMP
expression observed in leukocytes from inflammatory infiltrates.26
Moreover, the use of broad-spectrum MMP inhibitors has previ-
ously suggested that MMP proteolytic activity might be important
during leukocyte transmigration in vivo.27,28 Here, we have demon-
strated, by inhibition with mAbs, that MT1-MMP is required for
proper monocyte transmigration through activated endothelium.
No major role of MT1-MMP could be observed, however, in
monocyte transmigration through resting endothelium, suggesting
that MT1-MMP is relevant in an inflammatory situation. The
specific step or steps at which MT1-MMP is participating, as well
as the putative role that endothelial MT1-MMP might have in this
process, require further investigation.
To achieve directed and focused cellular migration, proteolytic
activity must be spatially regulated. In this regard, MT1-MMP has
previously been found at the leading edge of endothelial cells as
well as at the invadopodia of osteoclasts and melanoma cells.7,29,30
The localization of MT1-MMP in human leukocytes, however, has
not been defined before. We decided to investigate the subcellular
localization of MT1-MMP during monocyte migration on distinct
ligands, including activated endothelial cells. Hence, we have
shown for the first time that the small amount of MT1-MMP
present at the monocyte cell surface is clustered at membrane
protrusions related to motility, such as lamellipodia and filopodia,
when monocytes stimulated with MCP-1 are moving on FN or the
endothelial ligands VCAM-1 or ICAM-1. These data suggest that
monocytes would concentrate MT1-MMP at the cell surface for
regulation of migration and/or focused pericellular proteolysis.
This relocalization was observed at short times of 2 hours, in
accordance with the effect of anti–MT1-MMP mAb observed in the
functional assays as well as at longer times of 16 hours, suggesting
that MT1-MMP relocalization might continue during monocyte
Figure 7. MT1-MMP fibrinolytic activity is increased in human monocytes
attached to FN, VCAM-1, or ICAM-1. (Top) Proteolytic activity of MT1-MMP was
analyzed in cell extracts from monocytes attached to plates coated with 0.5% BSA,
20 g/mL FN, 10 g/mL FN fragments H89 and FN80, or 10 g/mL VCAM-1 or
ICAM-1 for 16 hours by fibrinogen zymography. LPS (10 ng/mL) stimulation for 16
hours was included as a positive control. The main 60 kDa fibrinolytic band observed
corresponds to the mature form of MT1-MMP. (Bottom) The arithmetic means and SD
of the fold induction of MT1-MMP fibrinolytic activity estimated by densitometry are
represented (an arbitrary value of 1 was assigned to the MT1-MMP activity in
monocytes attached to BSA). n  3. ***P  .01.
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passage to the inflammatory focus. Furthermore, we show by
confocal microscopy that MT1-MMP is also enriched at mem-
brane ruffles of MCP-1–stimulated monocytes adhered to and
transmigrating through activated endothelial monolayers. A dual
localization at the extended lamellipodia and more rarely at the
opposite site of polarized migratory monocytes was found. To
explore further the compartmentation of MT1-MMP during
monocyte transmigration, double staining with profilin, a marker
of cellular leading edge,19 was performed, and it showed
colocalization of both proteins at the advancing front. Because
clustering of MT1-MMP favors its activity, the enrichment of
MT1-MMP at motility-associated protrusions might explain its
functional role during monocyte migration and transmigration
through activated endothelial cells.
Additional mechanisms of MT1-MMP regulation together
with relocalization during monocyte migration were investi-
gated. Because ECM had been shown to regulate MT1-MMP
expression in other cell types, this question was next analyzed in
monocytes. We observed that monocyte interaction with FN or
with the specific FN fragments H89 and FN80 through integrins
41 and 51 significantly up-regulated both surface expres-
sion and total protein content of MT1-MMP, compared with the
slight increment observed upon attachment to BSA. This is in
accordance with the previously reported induction of MT1-
MMP in T lymphoblastoid cell lines adhered to FN.20 In
addition, data obtained using different doses of immobilized FN
versus soluble FN suggest that integrin receptor occupancy
rather than its aggregation is relevant for the observed MT1-
MMP cell-surface up-regulation. Therefore, integrin occupancy
could induce integrin redistribution or other intracellular events31
that might be either primarily involved in MT1-MMP up-
regulation or secondarily trigger signals that would lead to an
increase in MT1-MMP expression at longer times. In this
regard, the increase in both cell membrane and total content of
MT1-MMP protein only after long times of monocyte binding to
the substrates suggests an increase in its synthesis as reported
for LPS stimulation,12 although alternative mechanisms of
regulation cannot be ruled out. Because monocytes might also
encounter FN at the apical side of endothelial cells during
inflammation,32 MT1-MMP up-regulation could also take place
before transmigration, facilitating monocyte passage through
the tissue barriers toward the inflammatory focus. However,
because the increase of MT1-MMP expression is documented
after long times of monocyte binding to FN, it is more likely that
this acts as a late mechanism of further amplification.
As previously mentioned, monocytes tether, roll, and adhere to
endothelial cells before migrating into tissues. Remarkably, mono-
cyte interaction with activated endothelial cells also up-regulated
MT1-MMP surface expression. However, monocyte binding to
activated endothelium for long nonphysiologic times was required
for such increment in MT1-MMP expression. This result might
suggest that other factors present in a physiologic environment
such as flow or chemokines might act in concert with adhesion to
activated endothelium to up-regulate MT1-MMP expression in
monocytes. In this regard, it would be interesting to analyze
MT1-MMP regulation in monocyte-endothelium interactions un-
der flow conditions and/or in the presence of chemokines. In
addition, because activated endothelial cells express both VCAM-1
and ICAM-1 33 and anti–MT1-MMP mAb impaired migration on
these endothelial ligands, the effect of monocyte binding to these
proteins in MT1-MMP expression was also analyzed. Immobilized
VCAM-1 or ICAM-1 could similarly up-regulate MT1-MMP
expression in monocytes bound for long times, suggesting again
that other factors could be modulating this response in vivo.
VCAM-1– and ICAM-1–mediated up-regulation of MT1-MMP
expression might prepare monocytes for efficient migration through
the subendothelial matrix. In this regard, murine T cells express
more cell-surface MMP-2 and activate proMMP-2 better upon
interaction with VCAM-1–positive endothelial cells, likely through
an up-regulation of MT1-MMP in these cells,34 similar to that
demonstrated here for human monocytes. Engagement of integrin
41 by ligands like VCAM-1 or antibodies has also been reported
to increase MT1-MMP expression in intestinal mesenchymal cells,
pointing to a general, non-cell type–specific regulation of MT1-
MMP through 4 integrin signaling.35 Finally, both 4 integrin
ligands H89 and VCAM-1 similarly induced MT1-MMP up-
regulation in monocytes. This is in contrast to differences in the
regulation of proteases like MMP-9 by 4 integrin ligands CS1 and
VCAM-1 in human lymphoid cells.36
MT1-MMP activity has been tested indirectly in leukocytes
by its ability to activate proMMP-2. Thus, MMP-2 activation
was observed in stimulated human T lymphocytes as well as in
murine T lymphoblastoid cells after migration through VCAM-
1–expressing endothelial cells.34,37 Because monocytes do not
secrete proMMP-2, the only role assigned so far to MT1-MMP
in monocytes has been the putative activation of proMMP-2
from stroma or tumor cells.12 We have demonstrated here,
however, the direct ability of monocyte MT1-MMP to degrade
fibrinogen in zymography assays. Remarkably, this activity is
enhanced upon specific integrin-mediated interaction with FN or
FN fragments as well as with VCAM-1 or ICAM-1. In
agreement with this, 4 integrin is required for proper activation
of proMMP-2 by MT1-MMP in lymphocytes in the murine
experimental model of allergic encephalomyelitis.11,27 Thus,
MT1-MMP in monocytes might play a direct role in matrix
remodeling. MT1-MMP activity might be first regulated by
clustering of the protease at membrane protrusions after short
times of monocyte binding to distinct substrates as suggested by
immunofluorescence staining and be subsequently increased at
levels detected by zymography after longer times of adhesion to
the ligands. This up-regulation of MT1-MMP expression and
activity by long-lasting monocyte contact with either endothe-
lium or matrix might further regulate and increase MT1-MMP
participation in the inflammatory response.
Monocyte recruitment into tissues regulated by chemokines
like MCP-1 seems to play a major role in distinct chronic
inflammatory processes such as atherosclerosis.38 MMP inhibi-
tors have been actively tested in tumor therapy over the last few
years, but their potential in inflammatory disease has just started
to be explored.39-41 The data herein presented will be relevant for
the design of more specific MMP blocking reagents, leading to
novel and alternative therapeutic approaches to chronic inflam-
matory diseases.
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